Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Emergency Medicine
Volume 2016, Article ID 1393057, 3 pages
http://dx.doi.org/10.1155/2016/1393057
Case Report

Reversal of Dabigatran Using Idarucizumab in a Septic Patient with Impaired Kidney Function in Real-Life Practice

1Department of Emergency Medicine, Inselspital University Hospital, 3011 Bern, Switzerland
2Department of Haematology and Central Haematology Laboratory, Inselspital University Hospital, 3011 Bern, Switzerland
3Department of Cranio-Maxillofacial Surgery, Inselspital University Hospital, 3011 Bern, Switzerland

Received 13 May 2016; Accepted 12 July 2016

Academic Editor: Henry David

Copyright © 2016 Thomas C. Sauter et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Providência, E. L. Grove, S. Husted, S. Barra, S. Boveda, and J. Morais, “A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens,” Thrombosis Research, vol. 134, no. 6, pp. 1253–1264, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. T. C. Sauter, A.-L. Amylidi, M. E. Ricklin, B. Lehmann, and A. K. Exadaktylos, “Direct new oral anticoagulants in the emergency department: experience in everyday clinical practice at a Swiss university hospital,” European Journal of Internal Medicine, vol. 29, pp. e13–e15, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Fenger-Eriksen, A.-M. Münster, and E. L. Grove, “New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications,” Acta Anaesthesiologica Scandinavica, vol. 58, no. 6, pp. 651–659, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. J. S. Kalus, “Pharmacologic interventions for reversing the effects of oral anticoagulants,” American Journal of Health-System Pharmacy, vol. 70, no. 10, supplement 1, pp. S12–S21, 2013. View at Google Scholar
  5. C. V. Pollack, P. A. Reilly, J. Eikelboom et al., “Idarucizumab for dabigatran reversal,” The New England Journal of Medicine, vol. 373, no. 6, pp. 511–520, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Cuker, D. M. Siegal, M. A. Crowther, and D. A. Garcia, “Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants,” Journal of the American College of Cardiology, vol. 64, no. 11, pp. 1128–1139, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. A. J. P. Lewington, J. Cerdá, and R. L. Mehta, “Raising awareness of acute kidney injury: a global perspective of a silent killer,” Kidney International, vol. 84, no. 3, pp. 457–467, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Bellomo, J. A. Kellum, and C. Ronco, “Acute kidney injury,” The Lancet, vol. 380, no. 9843, pp. 756–766, 2012. View at Publisher · View at Google Scholar · View at Scopus